Skip to main content
. 2017 Oct 17;12(10):e0186213. doi: 10.1371/journal.pone.0186213

Fig 4. Restoration of HCV-suppressed antiviral signaling in the liver of humanized mice treated with DAAs.

Fig 4

(A) Serum levels of HCV in mice injected with 1.4 x 106 IU HCV intravenously. (B) HCV viral loads after treatment with Sofosbuvir (2.0mg daily), Daclatasvir (0.3mg daily), Asunaprevir (0.5mg twice daily) or DMSO vehicle control via oral gavage. (C) Protein expression of NS3, MAVS, IFITM1, and IRF3 following 14 days of DMSO treatment or DAA treatment in whole liver tissue via immunofluorescence staining. N = 3 mice per group. ****P<0.0001, NS = Not significant.